Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Related Keywords

,Recent Updates ,Translating Evidence ,Clinical Practice ,Versus Adjuvant Therapy ,Nsclc ,Early Nsclc ,Non Small Cell Lung Cancer ,Asco 2023 ,Localized Disease ,Presection ,Surgery ,Staging ,Chemoimmunotherapy ,Immunotherapy ,Ohio ,Molecular Testing ,Liquid Biopsy ,Tissue Biopsy ,Ngs Testing ,Egfr ,Talk ,